International Conference on Cancer Molecular Targets and Therapeutics in Clinical Oncology
Innovation in Molecular Targets and Projections of Novel Therapeutic Approaches
Oct 30-31, 2020
Chicago, United States of America
LexisConferences holds regular yearly meetings that are design to share and connect with scientists all over the world. We most enthusiastically announce “International Conference on Cancer Molecular Targets and Therapeutics in Clinical Oncology” which is to be held during October 30-31, 2020 at an exciting city Chicago, USA.
The main theme of the conference is “Innovation in Molecular Targets and Projections of Novel Therapeutic Approaches”.
Cancer Molecular Targets 2020 aims to provide a platform where the key strategic objective of this meeting is to communicate science and medical research between academia, and industry. Through inspiring sessions and whims of networking, you will learn to be even more audacious and bold than you are now and free to grow your mind, grow your business, and grow your bottom line. We can relieve you of the time and resource-draining elements of the events that you plan to hold. Poster and oral presentations, and thesis presentations will be included in the Conference Program.
We can relieve you of the time and resource-draining elements of the events that you plan to hold. This conference is intended to deliver a miscellaneous and current education that will keep medical professionals up to date with the latest methodologies, strategies and the present update in the field of Clinical Oncology.
The goal of organizing the Cancer Molecular Targets 2020 is to provide exposure to technologies and to deliver information about research work proceeding on Clinical Oncology.
If you would like to give a talk at the conference, please contact Program Manager.
DETAILS OF Clinical Oncology:
Cancer Molecular Targets 2020
Oct 30-31, 2020
Market Analysis for Clinical Oncology 2020
Cancer Therapeutics Market Outlook - 2026
The global cancer therapeutics market size was valued at $98,900 million in 2018 and is estimated to reach at $180,193 million by 2026, registering a CAGR of 7.7% from 2019 to 2026. Cancer therapeutics involves the use and administration of chemotherapy and oncology drugs to treat cancer.
Increase in cancer prevalence, surge in collaboration between pharmaceutical companies, and rise in cancer research are the key factors that augment the growth of the cancer therapeutics market. Furthermore, growth in geriatric population is expected to boost the market growth.
However, high cost associated with oncology drug development along with adverse effects associated with cancer therapeutics are some of the factors that restrain the market growth. Conversely, the upsurge in demand for personalized medicine and high potential of developing nations is expected to provide new opportunities for the market players in future.
Oncology Market Research Insights
The increasing adoption of radiotherapy equipment is expected to drive radiation oncology market growth through 2021. A key market trend expected to gain traction during the same forecast period is the increasing demand for proton therapy.
Overview of the global radiation oncology market
Technavio’s research analysis on the global radiation oncology market identifies that the increasing adoption of radiotherapy equipment will be one of the major factors that will have a positive impact on the growth of the market. The healthcare industry across the world highly relies on radiotherapy to manage most types of cancers. Different types of radiation therapies are used on more than half of all patients who are suffering from cancer. It has been estimated that approximately 9.5 million patients will be diagnosed with cancer by 2025. As a result, the low and mid-income countries are witnessing a rise in the installation of radiotherapy devices. It has been observed that from 1998 to 2010, the number of radiation therapy machines installed in Africa has increased by more than 75%. Radiotherapy is also recommended in high-income countries to cure localized diseases, palliate symptoms, and control the disease for incurable cancers. Our market research analysts predict that this market will grow at a CAGR of more than 5% by 2021.
The outsourcing of biosimilar manufacturing activities, a rising number of strategic collaborations, increasing cancer awareness, and a rise in R&D are the major trends impacting the global oncology biosimilars market.
Outlook of the global oncology biosimilars market
The global oncology biosimilars market will witness significant growth over the forecast period and is anticipated to grow at an impressive CAGR of around 31% during the forecast period. The growing need for cost-effective treatment methodologies will aid in the steady growth of this market during the forecast period. The high cost of branded biologic oncological drugs will compel patients to shift toward biosimilars as they are highly cost-effective. Since biosimilars cost 10%-30% lower than their parent counterparts, there is the presence of unmet medical needs for such products. This enables domestic manufacturers to market generic versions of the biologic compounds at a lower price, which in turn results in market growth.
Technavio’s market research analyst has estimated factors like the advent of new biosimilars to impel market growth during the forecast period. Unlike generic drugs, which have APIs that are identical to original drugs, biosimilars are similar to their originator biologic compounds. Biosimilars developed by different manufacturers differ from the original product as well as from each other. Since they are less expensive than biologics, patients will be able to afford and access biosimilars more easily than biologics.
In terms of geography, the EMEA region will be the largest market for oncology biosimilars during the forecast period. The market in this region will grow profoundly at a CAGR of over 31% and the prospects for market growth in this region will be driven by factors like the presence of well-defined regulatory guidelines, increasing geriatric population, and the patent expiries of biologics. Also, the presence of a strong generic culture in this region will spur the prospects for market growth until the end of 2020.
Steady growth is expected for the interventional oncology market through 2021 owing to rising demand for minimally invasive procedures. Geographically, the Americas accounts for the largest market share and we forecast the region to continue its dominance over the next few years.
Interventional oncology market outlook
According to the interventional oncology industry analysis, the global interventional oncology market is anticipated to grow at a steady rate and post a CAGR of more than 11% during the forecast period. The growing demand for minimally invasive (MI) procedures will drive the prospects for the global interventional oncology market growth until the end of 2021. Interventional oncology involves MI procedures to treat patients with other associated comorbidities and in inoperable patients.
Call for Submissions
Abstracts will be reviewed by the Abstract Review Board (ARB) of the conference
- Epigenetics in Cancer
- Gynecologic Oncology
- Protein Kinase Inhibitor
- Lung Cancer
- KRAS Gene
- Breast Cancer
- Liver Cancer
- DNA Damage and Repair
- Experimental Cancer Therapeutics
- Stomach Cancer
- Medical Oncology
- Pediatric Oncology
- Radiation Oncology
- Cancer Signaling Pathways
- Surgical Oncology
- Immuno-Oncology and Therapy
- Biological Marker
- Chimeric Antigen Receptor T cells CAR T-Cell
- Sarcomas, Carcinomas and Lymphomas